Why did Amedisys stock fall 21% in Q2?
Aug 05, 2021 · Amedisys expects full-year revenue between $2.230 billion and $2.245 billion. Analysts were looking for revenue of $2.32 billion. The company projects adjusted earnings per share in the range of ...
How much of Amedisys'stock is owned by institutions?
Apr 03, 2022 · Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMED shares have decreased by 9.4% and is now trading at $154.39. View which stocks have been most impacted by COVID-19.
What does Amedisys’ stock buyback plan mean for Amedisys?
Get the latest Amedisys, Inc. (AMED) stock news and headlines to help you in your trading and investing decisions.
What are analysts'target prices for Amedisys'stock?
Dec 02, 2021 · Dec. 2, 2021, 11:31 AM. It has been about a month since the last earnings report for Amedisys (AMED). Shares have lost about 22.9% in that time frame, underperforming the S&P 500.Will the recent ...
Why did amedisys stock go down today?
COVID-19 is the culprit behind this weaker-than-anticipated guidance. Amedisys stated that the pandemic has negatively impacted its ability to hire and retain staff in its hospice business.Aug 5, 2021
Is amedisys stock a good buy?
The company has an earnings growth rate of 12% for the next five years. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment. Over the past six months, the stock has gained 6.8% compared with the industry's 4.9% rally and 13.9% rise of the S&P 500.May 13, 2021
Will AMED stock go up?
Stock Price Forecast The 15 analysts offering 12-month price forecasts for Amedisys Inc have a median target of 181.00, with a high estimate of 230.00 and a low estimate of 162.00. The median estimate represents a +19.78% increase from the last price of 151.11.
Is amedisys a publicly traded company?
What stock exchange does AMED trade on? The company's shares trade on the NASDAQ Global Select Market (“NASDAQ”).
Is amedisys a Fortune 500 company?
Amedisys employs more than 21,000 individuals at more than 500 locations in 39 states and Washington, D.C. In 2010, annual revenues were approximately $1.6 billion. Amedisys was ranked 999 on the Fortune 1000 in 2011....Amedisys.TypePublic companyWebsiteamedisys.com13 more rows
Who is the CEO of amedisys?
Paul B. Kusserow (Dec 16, 2014–)Amedisys / CEO
How big is amedisys?
Chris Gerard is President & Chief Executive Officer of Amedisys (AMED), a publicly traded, leading provider of home health, hospice, palliative, personal care and high-acuity care services with over 22,000 employees in 39 states and the District of Columbia, making over 12.3 million patient visits per year.
Is Amedisys a buy right now?
14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 5 hold r...
How has Amedisys' stock been impacted by Coronavirus (COVID-19)?
Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organi...
When is Amedisys' next earnings date?
Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, April 27th 2022. View our earnings forecast for Amedisys .
How were Amedisys' earnings last quarter?
Amedisys, Inc. (NASDAQ:AMED) posted its quarterly earnings data on Wednesday, February, 23rd. The health services provider reported $1.18 EPS for t...
How will Amedisys' stock buyback program work?
Amedisys declared that its board has approved a share repurchase plan on Wednesday, August 4th 2021, which allows the company to buyback $100,000,0...
What guidance has Amedisys issued on next quarter's earnings?
Amedisys updated its FY 2022 earnings guidance on Wednesday, March, 16th. The company provided earnings per share (EPS) guidance of $5.230-$5.450 f...
What price target have analysts set for AMED?
14 analysts have issued 1-year price objectives for Amedisys' shares. Their forecasts range from $147.00 to $230.00. On average, they anticipate Am...
Who are Amedisys' key executives?
Amedisys' management team includes the following people: Paul B. K. Kusserow , Chairman & Chief Executive Officer Christopher T. Gerard , Presid...
What is Paul B. Kusserow's approval rating as Amedisys' CEO?
297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com . Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.
Is Amedisys a buy right now?
What stocks does MarketBeat like better than Amedisys?
10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock.
When is Amedisys' next earnings date?
Wall Street analysts have given Amedisys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amedisys wasn't one of them.
How were Amedisys' earnings last quarter?
Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.#N#View our earnings forecast for Amedisys.
How has Amedisys' stock been impacted by COVID-19?
Amedisys, Inc. (NASDAQ:AMED) announced its earnings results on Wednesday, August, 4th. The health services provider reported $1.69 earnings per share for the quarter, topping analysts' consensus estimates of $1.67 by $0.02. The health services provider earned $564.17 million during the quarter, compared to the consensus estimate of $565.48 million.
How will Amedisys' stock buyback program work?
Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMED stock has increased by 5.7% and is now trading at $180.25.#N#View which stocks have been most impacted by COVID-19.
What guidance has Amedisys issued on next quarter's earnings?
Amedisys declared that its Board of Directors has approved a stock buyback program on Wednesday, August 4th 2021, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 1.2% of its shares through open market purchases.
Returns On Capital Are A Standout For Amedisys (NASDAQ:AMED)
Amedisys updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided EPS guidance of $6.370-$6.490 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.960. The company issued revenue guidance of $2.23 million-$2.25 million, compared to the consensus revenue estimate of $2.32 billion.
Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic
What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Why Amedisys Stock Is Crashing Today
The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow
What happened Shares of Amedisys (NASDAQ: AMED) were down 21.2% as of 11:29 a.m. EDT on Thursday. The big decline came after the home health and hospice company announced its second-quarter results following the market close on Wednesday.
Amedisys (AMED) Beats Q2 Earnings Estimates
Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.
Is Weakness In Amedisys, Inc. (NASDAQ:AMED) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Amedisys (AMED) delivered earnings and revenue surprises of 3.05% and -0.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
It is hard to get excited after looking at Amedisys' (NASDAQ:AMED) recent performance, when its stock has declined 3.4...